Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro

Journal of Virological Methods

Volumn 222, Issue , 2015, Pages 150-157

  Hang, Xiaofeng ^a   Peng, Haoran ^b   Song, Hongyuan ^c   Qi, Zhongtian ^b   Miao, Xiaohui ^a   Xu, Wensheng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral activity; Cuprous oxide nanoparticles; HCV

Indexed keywords

COPPER OXIDE NANOPARTICLE; CUPROUS OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; COPPER; CUPROUS OXIDE; NANOPARTICLE;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUH7.5.1 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; DRUG EFFECTS; HEPACIVIRUS; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ATTACHMENT;

ANTIVIRAL AGENTS; CELL LINE; COPPER; HEPACIVIRUS; HEPATOCYTES; HUMANS; NANOPARTICLES; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 84947232758     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.06.010     Document Type: Article

References (37)

1. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197:633-642.
2. Bilian X. Intrauterine devices. Best. Pract. Res. Clin. Obstet. Gynaecol. 2002, 16:155-168.
3. Borkow G., Zhou S.S., Page T., Gabbay J. A novel anti-influenza copper oxide containing respiratory face mask. PLoS ONE 2010, 5:e11295.
4. 2 gas sensor. J. Am. Chem. Soc. 2012, 134:4905-4917.
5. DeRussy B.M., Aylward M.A., Fan Z., Ray P.C., Tandon R. Inhibition of cytomegalovirus infection and photothermolysis of infected cells using bioconjugated gold nanoparticles. Sci. Rep. 2014, 4:5550.
6. Elechiguerra J.L., Burt J.L., Morones J.R., Camacho-Bragado A., Gao X., Lara H.H., Yacaman M.J. Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol. 2005, 3:6.
7. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
8. Guisbiers G., Abudukelimu G., Hourlier D. Size-dependent catalytic and melting properties of platinum-palladium nanoparticles. Nanoscale Res. Lett. 2011, 6:396.
9. Hubacher D., Lara-Ricalde R., Taylor D.J., Guerra-Infante F., Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N. Engl. J. Med. 2001, 345:561-567.
10. Khandelwal N., Kaur G., Chaubey K.K., Singh P., Sharma S., Tiwari A., Singh S.V., Kumar N. Silver nanoparticles impair Peste des petits ruminants virus replication. Virus Res. 2014, 190:1-7.
11. Kieffer T.L., George S. Resistance to hepatitis C virus protease inhibitors. Curr. Opin. Virol. 2014, 8C:16-21.
12. Kohli A., Shaffer A., Sherman A., Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014, 312:631-640.
13. Lara H.H., Ayala-Nuñez N.V., Ixtepan-Turrent L., Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnol. 2010, 8:1.
14. Lara H.H., Ixtepan-Turrent L., Garza-Treviño E.N., Singh D.K. Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J Nanobiotechnol. 2011, 9:38.
15. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., Schultz M., Davis M.N., Kayali Z., Reddy K.R., Jacobson I.M., Kowdley K.V., Nyberg L., Subramanian G.M., Hyland R.H., Arterburn S., Jiang D., McNally J., Brainard D., Symonds W.T., McHutchison J.G., Sheikh A.M., Younossi Z., Gane E.J. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013, 368:1878-1887.
16. Lu L., Sun R.W., Chen R., Hui C.K., Ho C.M., Luk J.M., Lau G.K., Che C.M. Silver nanoparticles inhibit hepatitis B virus replication. Antivir. Ther. 2008, 13:253-262.
17. Matsumoto Y., Matsuura T., Aoyagi H., Matsuda M., Hmwe S.S., Date T., Watanabe N., Watashi K., Suzuki R., Ichinose S., Wake K., Suzuki T., Miyamura T., Wakita T., Aizaki H. Antiviral activity of glycyrrhizin against hepatitis C virus in vitro. PLOS ONE 2013, 8:e68992.
18. Mohammed, Fayaz A., Ao Z., Girilal M., Chen L., Xiao X., Kalaichelvan P., Yao X. Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int. J. Nanomed. 2012, 7:5007-5018.
19. Orlowski P., Tomaszewska E., Gniadek M., Baska P., Nowakowska J., Sokolowska J., Nowak Z., Donten M., Celichowski G., Grobelny J., Krzyzowska M. Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection. PLOS ONE 2014, 9:e104113.
20. Pungpapong S., Aqel B., Leise M., Werner K.T., Murphy J.L., Henry T.M., Ryland K., Chervenak A.E., Watt K.D., Vargas H.E., Keaveny A.P. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015, 61:1880-1886.
21. Qin Z.L., Ju H.P., Wang W.B., Ren H., Guan M., Zhao P., Qi Z.T. The Arg719 residue at the C-terminal end of the stem region in hepatitis C virus JFH-1 E2 glycoprotein promotes viral infection. Virus. Res. 2013, 172:1-8.
22. Rai M., Kon K., Ingle A., Duran N., Galdiero S., Galdiero M. Broad-spectrum bioactivities of silver nanoparticles: the emerging trends and future prospects. Appl. Microbiol. Biotechnol. 2014, 98:1951-1961.
23. Shionoiri N., Sato T., Fujimori Y., Nakayama T., Nemoto M., Matsunaga T., Tanaka T. Investigation of the antiviral properties of copper iodide nanoparticles against feline calicivirus. J. Biosci. Bioeng. 2012, 113:580-586.
24. Singh J., Srivastava M., Roychoudhury A., Lee D.W., Lee S.H., Malhotra B.D. Bienzyme-functionalized monodispersed biocompatible cuprous oxide/chitosan nanocomposite platform for biomedical application. J. Phys. Chem. B 2013, 117:141-152.
25. Song H., Wang W., Zhao P., Qi Z., Zhao S. Cuprous oxide nanoparticles inhibit angiogenesis via down regulation of VEGFR2 expression. Nanoscale 2014, 6:3206-3216.
26. Sunada K., Minoshima M., Hashimoto K. Highly efficient antiviral and antibacterial activities of solid-state cuprous compounds. J. Hazard. Mater. 2012, 235-236:265-270.
27. Tai A.W., Chung R.T. Treatment failure in hepatitis C: mechanisms of non-response. J. Hepatol. 2009, 50:412-420.
28. Turnlund J.R. Human whole-body copper metabolism. Am. J. Clin. Nutr. 1998, 67:960S-964S.
29. Variola F., Brunski J.B., Orsini G., Tambasco de., Oliveira P., Wazen R., Nanci A. Nanoscale surface modifications of medically relevant metals: state-of-the art and perspectives. Nanoscale 2011, 3:335-353.
30. Vausselin T., Calland N., Belouzard S., Descamps V., Douam F., Helle F., François C., Lavillette D., Duverlie G., Wahid A., Fénéant L., Cocquerel L., Guérardel Y., Wychowski C., Biot C., Dubuisson J. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 2013, 58:86-97.
31. Vijayakumar S., Ganesan S. Gold nanoparticles as an HIV entry inhibitor. Curr. HIV Res. 2012, 10:643-646.
32. Vonnemann J., Sieben C., Wolff C., Ludwig K., Böttcher C., Herrmann A., Haag R. Virus inhibition induced by polyvalent nanoparticles of different sizes. Nanoscale 2014, 6:2353-2360.
33. Wang Y., Zi X.Y., Su J., Zhang H.X., Zhang X.R., Zhu H.Y., Li J.X., Yin M., Yang F., Hu Y.P. Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells. Int. J. Nanomed. 2012, 7:2641-2652.
34. 2O particles: surface properties and applications in glucose sensing. Sensors (Basel) 2012, 12:13019-13033.
35. Xiang D.X., Chen Q., Pang L., Zheng C.L. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J. Virol. Methods 2011, 178:137-142.
36. Zhang J., Nie X., Ji Y., Liu Y., Wu X., Chen C., Fang X. Quantitative biokinetics and systemic translocation of various gold nanostructures are highly dependent on their size and shape. J. Nanosci. Nanotechnol. 2014, 14:4124-4138.
37. Zhong J., Gastaminza P., Chung J., Stamataki Z., Isogawa M., Cheng G., McKeating J.A., Chisari F.V. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 2006, 80:11082-11093.